Decoding the Liver's Silent Killer: How Growth Hormones, Metabolism, and Cancer Intertwine
"Unraveling the complexities of NAFLD, HCC, and the critical role of GH-JAK2-STAT5 signaling in maintaining liver health and preventing disease progression."
Obesity rates are climbing, and with them, a surge in metabolic disorders across the Western world. One of the most concerning is non-alcoholic fatty liver disease (NAFLD), a condition where the liver accumulates excess fat, mirroring the body’s struggle to process increasing caloric intake. NAFLD isn't just a benign condition; it's a gateway to more severe health problems, including liver cancer.
Growth hormone (GH) is a critical regulator, overseeing energy distribution and cellular repair. Its influence extends deeply into the liver, orchestrating key functions through the Janus kinase (JAK) 2 and signal transducer and activator of transcription (STAT) 5 pathway. This GH-JAK2-STAT5 axis governs liver health; when disrupted, metabolic chaos ensues, paving the way for NAFLD and, potentially, liver cancer.
While the absence of both STAT5 and JAK2 is linked to fat accumulation in the liver, new research indicates these proteins have distinctive, sometimes contradictory, roles in chronic liver disease and tumor development. By studying genetically modified animal models, we’re beginning to tease apart these complex mechanisms, offering hope for new treatments.
Metabolic Signals and Liver Cancer
Non-alcoholic fatty liver disease (NAFLD) is described as the hepatic manifestation of metabolic syndrome and is linked to early stages of liver cancer development. In mice, liver-specific deletion of STAT5 increased expression of genes involved in lipid uptake, including CD36 and VLDLR, as well as lipogenic and adipogenic genes. With a high-fat diet, CD36 and VLDLR expression rose further in STAT5-deficient mice.
Guidance for NAFLD Care
The 2018 AASLD document presents a data-supported approach to the diagnostic, therapeutic, and preventive aspects of NAFLD care. It explicitly distinguishes a guidance document from a guideline. A JAMA synopsis describes the 2022 AACE and AASLD guideline as addressing NAFLD management in primary care and endocrinology.
Tracing NAFLD’s History
A 2021 historical narrative traces descriptions of fatty liver from the nineteenth century to contemporary understanding of NAFLD in the twentieth and twenty-first centuries. A review of NAFLD histopathology identifies Ludwig’s seminal studies in 1980 as a key starting point, while noting that earlier studies also existed. A 2025 clinical history of NAFLD and MASLD treatment covers developments from the 1980s to today, including lifestyle interventions, vitamin E, and pioglitazone.
The Liver's Balancing Act: How it Manages Energy and Prevents Disease
The liver is the body's metabolic command center, responsible for processing proteins, lipids, and carbohydrates. It acts as both a storage facility and a distribution hub, absorbing, converting, and releasing essential substances. When this carefully orchestrated system malfunctions, the consequences can be dire, ranging from simple steatosis (fatty liver) to the more aggressive hepatocellular carcinoma (HCC).
- Glucose Regulation: The liver balances blood sugar levels, storing excess glucose as glycogen or releasing it when needed.
- Gluconeogenesis: When glycogen stores deplete, the liver creates glucose from other sources, ensuring the brain and other tissues receive the energy they require.
- Lipid Metabolism: The liver synthesizes and distributes fatty acids, triglycerides, and cholesterol, maintaining a delicate balance to prevent fat accumulation.
GH Signaling and Emerging Mechanisms
A 2025 review reports that hepatic growth hormone (GH) supports endocrine IGF-1 production and regulates substrate handling, lipid balance, and energy metabolism. It states that disrupted hepatic GH signaling promotes lipid accumulation and altered fatty-acid metabolism. A 2026 study notes that it remains unclear whether IL-21 accumulation and increased signaling arise before hepatocellular carcinoma (HCC) development or later drive its progression.
Limited Evidence and Causal Uncertainty
A systematic review and meta-analysis of GH therapy for metabolic dysfunction-associated steatotic liver disease reports that, from 1,047 initially searched articles, only three randomized controlled trials involving 120 patients met all criteria for analysis. In a study of tesamorelin and hepatic transcriptomic signatures in HIV-associated NAFLD, researchers cautioned that tissue was available at only two time points. They therefore could not determine whether observed gene-expression changes were a direct effect of tesamorelin or mediated indirectly by other biological effects.
Human Association and Mouse Findings
A systematic review and meta-analysis found NAFLD prevalence of 51% among patients with growth hormone deficiency (GHD), with a 95% confidence interval of 39–63%. Compared with controls matched for age, sex, or body mass index and without GHD, the pooled odds of NAFLD were higher in GHD patients (OR 4.27; 95% CI 1.33–13.68; p = 0.015). In a separate mouse model, liver-specific growth hormone receptor knockout mice developed severe hepatic steatosis by 6–8 weeks of age on a normal diet, attributed largely to increased triglyceride synthesis, compromised triglyceride export, and elevated free-fatty-acid supply.
Future Directions: Targeting JAK2 for Liver Health
The GH-JAK2-STAT5 pathway is central to understanding and treating fatty liver disease and preventing liver cancer. Impairing this pathway through the deletion of Stat5 or Jak2 leads to significant changes in lipid metabolism and accumulation of lipids. While both STAT5 and JAK2 are crucial for liver homeostasis, they play different roles in liver cancer development, partly due to differences in ROS generation and clearance. Targeting JAK2 may reduce oxidative stress and prevent liver damage.
Therapeutic Directions
A 2023 review reports that NAFLD affects approximately 25% of adults worldwide and that, at the time of publication, no pharmacologic therapy had been approved for it. A 2024 review summarizes treatment approaches including the Mediterranean diet, physical activity and exercise, and bariatric surgery. A 2025 article is titled as a review of current trends and emerging treatment strategies, but the supplied source description does not specify those strategies.
NAFLD Beyond the Liver
A 2021 review describes NAFLD as a worldwide public health problem affecting around 30% of adults and associated with liver-related and extrahepatic morbidity and mortality. It identifies cardiovascular disease as the leading cause of mortality among patients with NAFLD, followed by extrahepatic cancers. A 2023 review characterizes NAFLD as a systemic metabolic disease frequently accompanied by insulin resistance and hepatic and systemic inflammation, and links its increasing prevalence to the global obesity epidemic.